Page Title
Drug Development Pipeline
Lefamulin (Xenleta™)
Status
DiscontinuedTherapeutic Approach
Anti-Infective
Lefamulin (Xenleta™) is a compound that interferes with bacteria’s ability to make protein, which is required for bacteria to grow. It is available in both oral and intravenous (IV) formulations. Lefamulin is FDA-approved for the treatment of adults with community-acquired bacterial pneumonia (CABP). It was studied for its safety and pharmacokinetics in fighting infections in people with CF.
Status
A Phase 1 study to test the safety and pharmacokinetics of lefamulin in adults with CF was conducted. No further development in CF is planned at this time.
Sponsor
This program was sponsored by Nabriva Therapeutics. The program was conducted within the Therapeutics Development Network.

CONTACT THE CLINICAL TRIAL NAVIGATOR
Get personalized assistance and answers to your clinical trial questions.
Learn MoreSign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.
Learn More